Boston Scientific ( (BSX) ) has released its Q1 earnings. Here is a breakdown of the information Boston Scientific presented to its investors.
Boston Scientific is a global leader in medical technology, specializing in innovative solutions for cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases. The company has been advancing medical science for over 45 years, providing high-performance devices and therapies to improve patient health worldwide.
In the first quarter of 2025, Boston Scientific reported impressive financial results, with net sales reaching $4.663 billion, marking a 20.9% increase from the previous year. The company’s GAAP net income rose to $674 million, or $0.45 per share, while adjusted earnings per share stood at $0.75, reflecting significant growth and surpassing their guidance ranges.
Key highlights from the quarter include robust sales growth across all segments, with the Cardiovascular segment experiencing a remarkable 26.2% increase. Regionally, the United States led with a 31.1% rise in sales. The company also made strategic advancements, such as enrolling participants in the ELEVATE-PF clinical trial and acquiring Bolt Medical, Inc., enhancing its portfolio in cardiovascular treatments.
Looking ahead, Boston Scientific remains optimistic about its growth trajectory, projecting a full-year net sales increase of 15 to 17% on a reported basis. The company continues to focus on innovation and strategic acquisitions to drive long-term performance, positioning itself strongly in the competitive medical technology landscape.